What the GLP-1 Conversation Usually Leaves Out
What the GLP-1 Conversation Usually Leaves Out
If you haven't heard of GLP-1 medications by now, you will soon. Ozempic, Wegovy, Mounjaro, Zepbound, are everywhere, and the conversation around them tends to be loud, polarized, and light on nuance. Either they're framed as a miracle or a moral failing. Neither framing is accurate, and neither is particularly useful if you're actually trying to make a decision about your own body.
I've touched on GLP-1 medications before, weighing in on what they do well and where the conversation tends to get oversimplified. Here's the fuller picture, including some important new findings specific to women in perimenopause and menopause that weren't available even a year ago.
WHAT GLP-1 MEDICATIONS ACTUALLY ARE
GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally produces in response to eating. It signals your pancreas to release insulin, tells your brain you're full, and slows gastric emptying so food moves through your system more gradually. GLP-1 medications mimic and amplify this effect, reducing appetite and improving blood sugar regulation.
They were originally developed for type 2 diabetes. The weight loss effects were noticed along the way, and the rest is (recent) history. Since then, they've also gained FDA approval for conditions like obesity, reducing cardiovascular and kidney disease risk, and treating obstructive sleep apnea.
WHAT THEY ACTUALLY DO WELL
The efficacy data is strong. On average, people lose 10 to 21 percent of body weight over about 18 months, with up to 90 percent achieving a clinically significant result of 5 percent or more. Beyond the scale, these medications have also shown real benefit for cardiovascular risk reduction, improved insulin sensitivity, and reduced systemic inflammation. For women carrying substantial metabolic risk who haven't been able to make headway despite focused, sustained effort, this can be an appropriate and helpful tool.
They are not inherently bad medications. They are powerful medications that deserve a far more thoughtful conversation than either side of the internet is currently giving them.
THE MUSCLE QUESTION: WHAT'S ACTUALLY BEING DEBATED
Here's where the conversation gets more interesting, and more current, than what most folks have heard.
A significant portion of weight lost on these medications isn't fat. Across clinical trials, semaglutide has resulted in lean tissue losses of roughly 12 to 40 percent of total weight lost, and tirzepatide has shown losses in a similar 14 to 26 percent range. For comparison, lean mass is generally thought to make up about a quarter of weight lost through typical dietary weight loss, sometimes called the "quarter fat-free mass rule." So the concern isn't imaginary, GLP-1-related weight loss does appear to include a somewhat higher proportion of lean tissue than dieting alone typically produces.
But here's the part that typically does not make it into the conversation: this was the subject of active debate among endocrinologists at the 2026 American Diabetes Association Scientific Sessions. One expert argued there's no clear evidence that GLP-1-related weight loss causes frailty or sarcopenia, since the majority of weight lost is still fat, not lean tissue. Another expert pushed back on that reassurance. This is not settled science. Anyone telling you with total confidence that muscle loss on these medications is either a non-issue or a certain disaster is overstating what's actually known right now.
Some of the most recent mechanistic research is reassuring on one front. In both animal and early human data, GLP-1 medications appear to primarily reduce fat mass, with muscle function and mobility often preserved or even improved despite a modest reduction in absolute muscle mass. That's a big difference from the kind of muscle loss and weakness seen with starvation-based dieting.
At the same time, this is an active area of pharmaceutical development precisely because the concern is taken seriously. A combination therapy pairing semaglutide with a muscle-preserving drug called bimagrumab reduced the proportion of weight loss coming from lean tissue from roughly 21 percent down to about 7 percent in early trials, though we don't yet have this option widely available, and long-term functional outcomes are still being studied.
Where this leaves you practically:
The muscle loss risk is real enough to take seriously and act on, but not so catastrophic that it should be a blanket reason to avoid these medications if you're otherwise a good candidate. The research increasingly points toward one clear answer regardless of how the muscle debate ultimately resolves: adequate protein intake and resistance training substantially change this equation, and skipping both is the actual mistake, not the medication itself.
WHY THIS MATTERS MORE DURING PERIMENOPAUSE
This is where the conversation gets specific to you. Perimenopausal women are already dealing with hormonal shifts that affect metabolism, appetite regulation, and body composition. Current use of GLP-1 medications is actually highest specifically among this group, despite perimenopausal women being largely left out of the research that shaped how these drugs are prescribed and monitored in the first place.
You already know from our previous conversations that muscle mass naturally declines during this transition, and that decline matters for insulin sensitivity, metabolic rate, bone density, and long-term functional independence. Layering on a medication that may add its own lean-tissue loss on top of a life stage already prone to it isn't a reason for panic, but it is a legitimate reason for a more deliberate approach than "start the medication and see what happens."
Research also raises open questions about GLP-1s potentially affecting vasomotor symptoms like hot flashes and night sweats, along with bone health. Whether these effects are ultimately beneficial or harmful for women's health during this transition remains unknown at this point. Some limited evidence points toward potential improvement in menopausal symptoms, but that data is still early and shouldn't be treated as settled.
The honest summary from researchers actively studying this: we currently lack adequate research to guide fully evidence-based prescribing and decision-making specifically for perimenopausal women, even though this is one of the populations using these medications the most. That gap is something to factor in, not as a reason for alarm, but as a reason to be an informed, active participant in your own care rather than assuming your provider automatically has perimenopause-specific data to draw from.
PROTEIN AND RESISTANCE TRAINING AREN'T OPTIONAL HERE
Given everything above, this is the part of the conversation that matters most and gets skipped most often.
GLP-1 medications reduce appetite broadly. They don't distinguish between fat tissue and muscle tissue when your intake drops. Without adequate protein and intentional resistance training, a sizable portion of the weight lost can come from the tissue you most need to protect during this life stage.
Practically, that means prioritizing protein at every meal even when appetite is significantly reduced, which takes deliberate effort on a medication designed to make eating less appealing. It means resistance training two to three times weekly isn't a ‘nice-to-have’, it's necessary for offsetting lean tissue loss. And it means working with a provider who's tracking body composition, not just the number on the scale, since two people can lose the same amount of weight with very different outcomes for their long-term strength and metabolic health.
THE REBOUND QUESTION
One of the most common concerns is what happens when you stop. The data here is significant enough to take seriously. A recent systematic review found that within one year of stopping a GLP-1 medication, people regain an average of 60 percent of the weight they lost during treatment. Semaglutide specifically showed the highest regain of the medications studied.
This isn't a moral failing or evidence of weak willpower. It reflects what happens when a powerful appetite-suppressing medication is removed without addressing the underlying metabolic drivers in parallel: blood sugar regulation, hormonal balance, cortisol, gut health. There is some reassuring nuance here too: the regain trajectory is nonlinear and tends to plateau below your original starting weight, suggesting some benefit may persist even after stopping, at least at the population level. But "some benefit persists" is a very different outcome than "the results are permanent," and going in with accurate expectations matters either way.
Using a GLP-1 medication as a bridge while actively addressing root causes is a fundamentally different clinical picture than using one indefinitely without that other work happening alongside it.
NUTRIENTS TO KEEP AN EYE ON
Reduced food volume means reduced nutrient intake across the board, not just calories. Protein remains the top priority, both for preserving muscle and for supporting hormone production and thyroid function. B12, zinc, iron, and magnesium should all be monitored as intake drops, since deficiencies in these are common even without appetite suppression in the picture.
One caution specific to B12: many compounded GLP-1 formulations already contain added B12. More isn't automatically better here. A chronically elevated B12 isn't entirely benign, so it is important to track this rather than assuming more is simply better.
THE BOTTOM LINE
GLP-1 medications are neither a miracle nor a shortcut, and they're not a moral issue in either direction. They're a powerful clinical tool with clear benefits, open questions, and responsibilities that come with using them well. That's especially true for women navigating this specific hormonal transition, where the research is still catching up to how widely these medications are already being used.
If you're a good candidate and considering one, a few things can change this equation substantially in your favor: adequate protein, a resistance training plan, and a provider who's paying attention to body composition and perimenopause-specific factors, not just the number on the scale.
Sources
RAND Corporation, "GLP-1 Agonists in Perimenopause: Unique Risks and Potential Opportunities"
Medscape, "Should We Be Concerned About Muscle Loss With GLP-1s?" — coverage of the 2026 ADA Scientific Sessions debate
Cell Reports Medicine, "Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans"
AJMC, "GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale"
